BioStem Technologies, Inc. · NASDAQ:BSEM
BioStem Technologies — Q2 2026 Earnings Presentation
22 slides from BioStem Technologies's earnings presentation, August 2026
Slide 1: Company Presentation
Company Presentation August 2026
Slide 2: Legal Disclaimers
Legal Disclaimers Disclaimer This presentation (this “Presentation”) is provided for informational purposes only and has been prepared to assist interested parties in a proposed private placement (the “Private Placement”) of equity securities (the “Securities”) of BioStem Technologies, Inc. (the “Co
Slide 3: Positioned for strong growth
Positioned for strong growth Our To create and deliver the most advanced regenerative healing technologies in the world Mission 10+ 60+ 4x $26B Products Reps Capacity TAM Broad commercial Expanding direct and Significant US surgical and chronic product portfolio, ISA commercial manufacturing capacit
Slide 4: Surgical procedures need more effective healing solutions
Surgical procedures need more effective healing solutions Patient Need Economic Impact Over 40M major surgical Infections and post-surgical procedures performed in complications cost the the U.S. each year1 health system an estimated $30B+ each year3 1 in 9 Americans reported undergoing a surgical S
Slide 5: Regenerative medicine improves healing
Regenerative medicine improves healing Modulate Minimize Prevent Manage Reduce Inflammation Scarring & Infection Pain Complications Adhesion Perinatal Regenerative Sterile, timely care Controlling Effective allografts optimize healing reduces reduces infections, inflammation management the healing s
Slide 6: Large underserved ~$26B US soft tissue allograft opportunity
Large underserved ~$26B US soft tissue allograft opportunity Driving adoption of perinatal tissue allografts across multiple market segments 1 Orthopedics/Sports Medicine 4 Urology US TAM: ~$3.1B US TAM: ~$1.2B Knee Osteoarthritis | Soft Tissue Repair Radical Prostatectomy | Urethral / | Trauma Uret
Slide 7: Acquisition catalyzes new market access and growth
Acquisition catalyzes new market access and growth Broader product portfolio, diversified customer base and new commercial engine Before: After: • Wound-centric BioTissue • • Surgical-centric Commercial payors + CMS • CMS dependent • Physician office weighted Acquisition • Hospital + office • Single
Slide 8: Shift to hospital market expected to create a stable and repeatable growth model
Shift to hospital market expected to create a stable and repeatable growth model Why hospitals matter: • Broad surgical applications with Before established reimbursement • Reduced dependence on CMS wound 100% Product based reimbursement (PBR) pricing • Products purchased as an expense under the DRG
Slide 9: Comprehensive portfolio drives growth across all sites of care
Comprehensive portfolio drives growth across all sites of care Three differentiated platform technologies: Portfolio breadth enables positioning in target markets to address the clinical need Next step Physician Office / Wound Hospital / Surgical Add BioRetain products to GPOs where Vendaje® Clarix
Slide 10: Our Regenerative Medicine Solutions
Our Regenerative Medicine Solutions A comprehensive portfolio of perinatal tissue allografts Orthopedics/Sports Medicine · Foot & Ankle · Urology / Colorectal · Chronic Wound Care NON-WOUND / SURGICAL WOUND Spine · Women's Health Clarix 1K C Clarix 100 C Clarix Flo C Neox 1K C Neox 100 C Neox RT S C
Slide 11: Strong foundation of clinical evidence
Strong foundation of clinical evidence Clinical and technical data support value-analysis review, physician adoption and specialty expansion 400+ DFU / VLU KOLs 1.2M+ Publications across 90+ Product applications, Randomized evidence Specialty champions to technologies and proven widespread milestone
Slide 12: Expanding our acquired direct salesforce to cover highest opportunity territories
Expanding our acquired direct salesforce to cover highest opportunity territories Market selection criteria GPO access, hospital density, relevant procedure volume, commercial payor mix, physician champions and salesforce coverage Direct W2 priority ISA / distributor role Strategic hospital clusters
Slide 13: Land and expand commercial strategy
Land and expand commercial strategy Unlocks full hospital TAM Steps to “Land” GPO/IDN Physician Value First cases Expand use access champion analysis Reorder Identifies Clinical and Initial purchase Premier, Vizient, cadence and procedure use economic orders and HPG and other account cases, review;
Slide 14: Favorable outcomes and economics – example #1
Favorable outcomes and economics – example #1 Robot-Assisted Radical Prostatectomy (RARP) • Clinical model with 100 patients to measure functional recovery rates after RARP, with and without Clarix®1 • Patients collectively spent $113,880 more in treatment over a 12-month period when compared to pat
Slide 15: Favorable outcomes and economics – example #2
Favorable outcomes and economics – example #2 Ureteroplasty: Autograft vs. Allograft • Compares clinical outcomes of a single surgeon using Clarix® as an adjunct versus the available literature in Ureteroplasty • Highlights the post-operative complications, donor site morbidity, stricture reoccurren
Slide 16: Immediate opportunity and focus
Immediate opportunity and focus Urology procedures are a strong landing point before expanding to other specialties Robot-Assisted Radical Prostatectomy (RARP) with UC (Clarix 1K)1 1 Urology US TAM: ~$1.2B • Statistically significant higher Radical Prostatectomy | Urethral / continence rates at 1, 3
Slide 17: Immediate opportunity and focus
Immediate opportunity and focus Foot and ankle surgery is another landing point with a strong foundation of evidence Land and Expand – Foot and Ankle 1 Urology • Large opportunity US TAM: ~$1.2B • Favorable economics Radical Prostatectomy | Urethral / • Positive clinical data Ureteral Strictures | R
Slide 18: Upgrading FDA regulatory status increases value
Upgrading FDA regulatory status increases value Strengthens marketing claims and physician confidence Current status 510(k) Regulatory Pathway Catalyze Commercial launch • Clarix/ Neox Flo sold as • Differentiates the product • 510(k) cleared HCT/P 361 product • Strengthens marketability • Launch ta
Slide 19: Manufacturing tech transfer as a 2027 margin catalyst
Manufacturing tech transfer as a 2027 margin catalyst At Acquisition BioStem Today 1H 2027 BioTissue supply Process transfer, Target transfer of Neox agreement covers quality readiness, and Clarix Neox/Clarix production commercial manufacturing to for 12+ months forecasting and existing BioStem capa
Slide 20: Financial highlights
Financial highlights Second quarter 2026 results reflected positive integration of the BioTissue acquisition and sequential growth First Quarter 2026 Results Second Quarter 2026 Results • Revenue: $6.1M • Revenue: $7.9M • Gross margin: 61% • Gross margin: 61% • OpEx: $12.6M • OpEx: $13.2M • Adj EBIT
Slide 21: Building momentum through strategic integration and expansion
Building momentum through strategic integration and expansion Significant unmet National distribution need in the Differentiated, broad footprint with hospital, with and clinically proven expanding payor accessible $26B US product portfolio access TAM Accredited Vertically integrated manufacturing f
Slide 22: Thank you
Thank you